Trial Profile
Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2010
Price :
$35
*
At a glance
- Drugs Pegargiminase (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Polaris Pharmaceuticals
- 15 Apr 2010 New trial record
- 29 Mar 2010 Results published in the Journal of Clinical Oncology.